May 14, 2025FinancialNotice concerning differences in non-consolidated financial results between FY2023 and FY2024 (PDF 108.74 KB)
May 14, 2025CorporateTerumo and WuXi Biologics Enter into Agreement on a Drug Product Plant in Leverkusen, GermanyExpanding production capacity and global responsiveness of Terumo’s CDMO business
Top Management Message Message from top management to shareholders and investors. /investors/management/message Corporate Governance /about/governance Compliance /about/compliance Leadership Team /about/leadership Business Risks Major risks that may affect the business performance and financial position of the Terumo Group are described. /investors/management/risk IR Policy /investors/management/ir_policy Disclaimer /investors/disclaimer
